drugset / Trial / NCT00935597
Host Dendritic Cells in Allograft Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess preliminary efficacy and to determine the safety and feasibility of ex vivo generated dendritic cell (HDC) infusion with and without donor lymphocyte infusion (DLI) after allogeneic stem cell transplant (SCT). We also wish to establish the feasibility of apheresis shipment as well as vaccine shipment and stability in the population.
Timeline
- Start
- 2009-08
- Primary completion
- 2013-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MSSM/BIIR HDC Vax-001 | Unknown | 100000 cells/kg | Other |